• Home
  • About
  • Portfolio
  • Meet the Team
  • News
  • Contact
  • Investor Portal

  • info@chv.vc

  • 129 South Street, 4th Floor, Boston, MA 02111

Home / News / Sera Prognostics (: Page 2)

Sera Prognostics


Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
  • September 15, 2021
  • -
  • Sera Prognostics
Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility
  • August 17, 2021
  • -
  • Sera Prognostics
Sera Prognostics Announces Pricing of Initial Public Offering
  • July 14, 2021
  • -
  • Sera Prognostics
Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk of Preterm Birth
  • May 19, 2021
  • -
  • Sera Prognostics
Evaluation of Health and Economic Benefit of the PreTRM® Test-And-Treat Strategy to Improve Maternal and Infant Health Among Commercially Insured in the US
  • May 18, 2021
  • -
  • Sera Prognostics
Sera Prognostics Completes $100 Million Series E Financing
  • April 28, 2021
  • -
  • Sera Prognostics
Sera Prognostics Appoints Thomas J. Garite, M.D. as Vice President of Clinical Sciences
  • June 24, 2020
  • -
  • Sera Prognostics
Sera Publishes Data Showing PreTRM Test Can Predict Delivery Prior to 32 Weeks
  • June 4, 2020
  • -
  • Sera Prognostics
Show Less
Show More

Let’s Connect.

Contact Us
https://chv.vc/wp-content/uploads/2020/08/footer-logo.png

Sitemap

  • Home
  • About
  • Portfolio
  • Meet the Team
  • News
  • Contact
  • Investor Portal

About

Catalyst Health Ventures (CHV) is a venture capital fund investing in transformative medical technologies addressing global unmet needs.

Contact

  • info@chv.vc

Boston Web Design by GoingClear